ClinicalTrials.gg
CompletedNCT03905707EASE SBS 2Updated Sep 8, 2026

Evaluation of Long Term Safety and Efficacy of Glepaglutide in Treatment of SBS

A Phase 3 interventional study of glepaglutide in Short Bowel Syndrome, sponsored by Zealand Pharma. Completed at 27 sites in 9 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by Zealand Pharma · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 80 studies in Short Bowel Syndrome with a site in United States — 11 open to participants now, 15 under way, 4 of them phase 3. Short Bowel Syndrome · United States.

Enrollment
4th of 66
150 · median 23
Started
2019
the only one that year
Phase 3
20 of 80
2 open now
Registered
56th of 80
by date
Lead sponsor
5 of 80
Zealand Pharma

Among the 80 studies in Short Bowel Syndrome with a site in United States, this one is the 4th largest by enrollment of the 66 interventional ones that give a count, is the only one that started in 2019, is one of 20 in phase 3, and was the 56th registered.

Short Bowel Syndrome

159 studies on the registry are indexed under Short Bowel Syndrome; 24 are open to participants now.

Browse Short Bowel Syndrome studies →

Open to participants now

11 of the 80 studies in Short Bowel Syndrome with a site in United States are open now. Recruiting first, the newest first:

6 more — sign in →

All 11 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 18 Short Bowel Syndrome studies recruiting now, 8 (44%) set no upper age limit and 8 (44%) stop at 75 or younger; 9 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Short Bowel Syndrome with a site in United States, or all of them as a file.
02

Study summary

The primary objective of the trial is to evaluate the long-term safety of glepaglutide treatment in patients with short bowel syndrome (SBS).

Glepaglutide is the International Nonproprietary Name and USAN for ZP1848.

Read the detailed description

A Double-Blind Phase 3 Extension Trial Assessing the Long Term Safety and Efficacy of Glepaglutide in Patients with Short Bowel Syndrome (SBS)

03

Conditions studied

  • Short Bowel Syndrome

Browse trials for

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • obtained before any trial-related activity
  • Completed the lead-in trial (ZP1848-17111) or completed the Phase 2 trial (ZP1848-15073)

Exclusion criteria

Exclusion Criteria:

  • Withdrawal of consent from the lead-in trial
  • Any condition or disease or circumstance that in the Investigator's opinion would put the patient at any undue risk, prevent completion of the trial, or interfere with the analysis of the trial results
  • Use of GLP-1, GLP-2, human growth hormone, somatostatin, or analogs thereof, within 3 months prior to Screening
  • Females of , who are pregnant, breast-feeding, intend to become pregnant or are not using highly effective methods
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (actual)

Study arms

  • Experimental
    Glepaglutide SC injections twice weekly

    Glucagon-Like Peptide-2 (GLP-2) analog, 10 mg subcutaneous injection twice weekly. In this long term safety study, there is no placebo arm.

    Drug: glepaglutide

  • Experimental
    Glepaglutide SC injections once weekly and placebo once weekly

    Glucagon-Like Peptide-2 (GLP-2) analog, 10 mg subcutaneous injection once weekly and placebo once weekly. In this long term safety study, there is no placebo arm.

    Drug: glepaglutide

Interventions

  • Glucagon-Like Peptide-2 (GLP-2) analog

    Also known as: ZP1848

06

What researchers measure

Primary outcomes

  1. Safety - Adverse Events

    Incidence and type of Adverse Events

    Time frame: 2 years

Secondary outcomes

  1. Safety - Serious Adverse Events

    Incidence and type of Serious Adverse Events

    Time frame: 2 years

  2. Safety - Adverse Events of Special Interest

    Incidence and type of Adverse Events of Special Interest

    Time frame: 2 years

  3. Safety - Changes in blood pressure from baseline

    Changes in systolic and diastolic blood pressure will be reported

    Time frame: 2 years

  4. Number of patients with clinically significant changes in 12-Lead electrocardiogram (ECG)

    Number of patients with clinically significant changes in ECG will be reported

    Time frame: 2 years

  5. Immunogenicity - Occurrence of anti-drug antibodies

    Occurrence of antibodies against glepaglutide

    Time frame: 2 years

  6. Change in weekly Parenteral Support (PS) volume

    Change in weekly PS volume from baseline

    Time frame: 2 years

  7. Number of patients with 20 percent reduction in PS volume

    Achieving at least 20 percent reduction in weekly PS volume from baseline

    Time frame: 2 years

  8. Days off PS

    Achieving 1 or more days per week off PS

    Time frame: 2 years

  9. Weaned off PS

    Reduction in weekly PS volume of 100 percent (weaned off)

    Time frame: 2 years

  10. Changes in fluid composite effect

    Reduction in PS plus reduction in oral fluid intake plus increase in urine volume from baseline

    Time frame: 2 years

  11. Energy content (lipids)

    Change in lipids content (in kcal/L or kjoule/L) of PS from baseline

    Time frame: 2 years

  12. Energy content (glucose)

    Change in glucose content (in kcal/L or kjoule/L) of PS from baseline

    Time frame: 2 years

  13. Energy content (amino acids)

    Change in amino acids content (in kcal/L or kjoule/L) of PS from baseline

    Time frame: 2 years

  14. Days on PS

    Change in number of days on PS per week from baseline

    Time frame: 2 years

  15. Number of patients with 40 percent change in PS volume per week

    Achieving 40 percent in PS volume from baseline

    Time frame: 2 years

07

Study locations

27 sites
  • Georgetown University Medical Center
    Washington D.C., District of Columbia 20007, United States
  • University of Chicago Children's Hospital
    Chicago, Illinois 60637, United States
  • Mayo Clinic College of Medicine
    Rochester, Minnesota 55905, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198-3285, United States
  • Mount Sinai Hospital
    New York, New York 10029, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • Vanderbilt University Medical Center, Nashville
    Nashville, Tennessee 68198-3285, United States
  • UZ Leuven
    Leuven, Belgium
  • The Royal Alexandra Hospital
    Edmonton, Canada
  • Western University
    London, N6A 4V2, Canada
  • University Health Network - Toronto General Hospital
    Toronto, Canada
  • Rigshospitalet
    Copenhagen, Denmark
  • Hôpital Beaujon
    Clichy, France
  • Centre Hospitalier Lyon-Sud
    Pierre-Bénite, France
  • Charité - Universitätsmedizin Berlin
    Berlin, Germany
  • Universitätsklinikum Bonn
    Bonn, 53127, Germany
  • Universitätsklinikum Frankfurt - Med. Klinik I
    Frankfurt, Germany
  • Asklepios Kliniken Hamburg GmbH
    Hamburg, Germany
  • Universitätsmedizin Rostock
    Rostock, Germany
  • UMC Radboud Nijmegen
    Nijmegen, Netherlands
  • Wojewodzki Specjalistyczny Szpital im. M. Pirogowa w Lodzi
    Lodz, Poland
  • Solumed
    Poznan, Poland
  • Szpital Skawina sp. z o.o. im. Stanley Dudricka
    Skawina, Poland
  • St Mark's Hospital
    Harrow, United Kingdom
  • UCLH Foundation NHS Trust
    London, United Kingdom
  • University of East Anglia
    Norwich, United Kingdom
  • University Hospital Southampton NHS Foundation Trust
    Southampton, United Kingdom
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in Apr 2026, 83 months.

Of 26 industry-sponsored phase 3 interventional studies under Short Bowel Syndrome, half reached primary completion within 36 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's 83 months is above that.

Counting every sponsor, half of 27 studies reached it within 37 months; a quarter within 24 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2019
First posted
Apr 5, 2019
StartActual
May 7, 2019
Primary completionActual
Apr 30, 2026
CompletionActual
Apr 30, 2026
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03905707
Lead sponsor
Zealand Pharma
Responsible party
Sponsor
First posted
Apr 5, 2019
Start date
May 7, 2019
Primary completion
Apr 30, 2026
Completion
Apr 30, 2026
Last update
Sep 8, 2026

Study contacts

Zealand Pharma
study director · Zealand Pharma

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Glepaglutide

Start the discussion